Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 4.99% and Operating profit at 4.16% over the last 5 years
2
The company declared positive results in Mar'25 after negative results in Dec'24
3
With ROE of 12.59%, it has a attractive valuation with a 2.52 Price to Book Value
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 95,180 Million (Large Cap)
20.00
NA
2.26%
-0.28
12.75%
2.40
Revenue and Profits:
Net Sales:
11,603 Million
(Quarterly Results - Mar 2026)
Net Profit:
2,031 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.68%
0%
-7.68%
6 Months
-6.09%
0%
-6.09%
1 Year
-7.77%
0%
-7.77%
2 Years
-7.52%
0%
-7.52%
3 Years
-11.04%
0%
-11.04%
4 Years
-3.93%
0%
-3.93%
5 Years
-48.41%
0%
-48.41%
Yunnan Baiyao Group Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.99%
EBIT Growth (5y)
4.16%
EBIT to Interest (avg)
49.51
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.29
Sales to Capital Employed (avg)
0.92
Tax Ratio
19.42%
Dividend Payout Ratio
44.52%
Pledged Shares
0
Institutional Holding
0.01%
ROCE (avg)
15.36%
ROE (avg)
10.59%
Valuation key factors
Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
2.52
EV to EBIT
18.48
EV to EBITDA
17.15
EV to Capital Employed
3.26
EV to Sales
2.18
PEG Ratio
1.33
Dividend Yield
4.25%
ROCE (Latest)
17.64%
ROE (Latest)
12.59%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : Jun 2017
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.01%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
11,602.60
10,532.80
10.16%
Operating Profit (PBDIT) excl Other Income
2,060.50
376.70
446.99%
Interest
5.10
8.80
-42.05%
Exceptional Items
16.40
28.70
-42.86%
Consolidate Net Profit
2,030.60
400.80
406.64%
Operating Profit Margin (Excl OI)
177.60%
25.50%
15.21%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 10.16% vs 12.60% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 406.64% vs -64.98% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
41,013.30
39,855.50
2.90%
Operating Profit (PBDIT) excl Other Income
5,149.30
4,923.30
4.59%
Interest
30.30
73.90
-59.00%
Exceptional Items
105.20
103.30
1.84%
Consolidate Net Profit
5,189.90
4,767.10
8.87%
Operating Profit Margin (Excl OI)
115.40%
114.70%
0.07%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 2.90% vs 2.45% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 8.87% vs 15.63% in Dec 2024
About Yunnan Baiyao Group Co., Ltd. 
Yunnan Baiyao Group Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






